{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:30:36Z","timestamp":1777552236897,"version":"3.51.4"},"reference-count":17,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDT"],"published-print":{"date-parts":[[2019,1,25]]},"abstract":"<jats:sec>\n<jats:title>Aim:<\/jats:title>\n<jats:p> The role of rifaximin in the prevention of Spontaneous Bacterial Peritonitis (SBP) is\nnot well studied. The aim of this meta-analysis was to evaluate the role of rifaximin in the prevention\nof SBP.<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Methods: <\/jats:title>\n<jats:p>A computerized literature search for relevant clinical trials was conducted during August\n2017. Data on Frequency of SBP, the success rate of prevention of SBP, mortality rate, hepatorenal\nsyndrome, septic shock, hepatic encephalopathy, and GIT bleeding were extracted and pooled as Risk\nRatio (RR) with their 95% Confidence Interval (CI) in a meta-analysis model. Heterogeneity was assessed\nby Chi-square test.<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p> Six studies involving 973 patients were included in the final analysis. The pooled effect estimate\nshowed that the rifaximin plus norfloxacin group had less incidence of SBP (RR 0.58, 95%\nCI[0.37, 0.92], P=0.02) and hepatic encephalopathy (RR 0.38, 95% CI[0.17, 0.84], P=0.02) than the\nnorfloxacin-based regimen group. No significant difference between rifaximin and norfloxacin in\nterms of frequency of SBP and success rate of primary prevention of SBP (RR 0.49, 95% CI [0.24,\n1.01], P=0.05; RR1.21, 95% CI [0.95, 1.55], P=0.13, respectively).<\/jats:p><\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion: <\/jats:title>\n<jats:p>Based on our analysis, Rifaximin is a promising drug and appears to be a good alternative\nto norfloxacin in the prevention of SBP.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1389450119666180924145156","type":"journal-article","created":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T03:40:54Z","timestamp":1538106054000},"page":"380-387","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Safety and Efficacy of Rifaximin in Prophylaxis of Spontaneous Bacterial Peritonitis: A Systematic Review and Meta-analysis"],"prefix":"10.2174","volume":"20","author":[{"given":"Amr","family":"Menshawy","sequence":"first","affiliation":[{"name":"Medical Research Education and Practice Association (MREP), Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Mattar","sequence":"additional","affiliation":[{"name":"Medical Research Education and Practice Association (MREP), Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirolos","family":"Barssoum","sequence":"additional","affiliation":[{"name":"Medical Research Education and Practice Association (MREP), Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ammar M.","family":"AboEl-Naga","sequence":"additional","affiliation":[{"name":"Medical Research Education and Practice Association (MREP), Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haitham Mohamed","family":"Salim","sequence":"additional","affiliation":[{"name":"Medical Research Education and Practice Association (MREP), Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Mesbah Fahmy","family":"Mohamed","sequence":"additional","affiliation":[{"name":"Medical Research Education and Practice Association (MREP), Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Elgebaly","sequence":"additional","affiliation":[{"name":"Medical Research Education and Practice Association (MREP), Cairo, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherief","family":"Abd-Elsalam","sequence":"additional","affiliation":[{"name":"Department of Tropical Medicine & Infectious Diseases, Faculty of Medicine, Tanta University, Tanta, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1097\/MEG.0000000000000724","volume":"28","author":"Elfert A.","year":"2016","unstructured":"Elfert A, Abo Ali L, Soliman S, Ibrahim S, Abd-Elsalam S.  Randomized-controlled trial of rifaximin  norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/gutjnl-2011-300779","volume":"61","author":"Wiest R.","year":"2012","unstructured":"Wiest R, Krag A, Gerbes A.  Spontaneous bacterial peritonitis: Recent guidelines and beyond.","journal-title":"Gut"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1053\/jhep.2002.30082","volume":"35","author":"Fernandez J.","year":"2000","unstructured":"Fernandez J, Navasa M, Gomez J.  Bacterial infections in cirrhosis: Epidemiological changes with invasive procedures and norfloxacin prophylaxis.","journal-title":"Hepatology"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S0168-8278(94)80241-6","volume":"21","author":"Runyon B.A.","year":"1994","unstructured":"Runyon BA, Squier S, Borzio M.  Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis.","journal-title":"J Hepatol"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1159\/000444551","volume":"34","author":"Garcia-Tsao G.","year":"2016","unstructured":"Garcia-Tsao G.  Current management of the complications of cirrhosis and portal hypertension\u202f: Variceal hemorrhage, ascites, and spontaneous bacterial peritonitis.","journal-title":"Dig Dis"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0168-8278(12)60002-6","volume":"56","author":"Fern\u00e1ndez J.","year":"2012","unstructured":"Fern\u00e1ndez J, Gustot T.  Management of bacterial infections in cirrhosis.","journal-title":"J Hepatol"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/1471-2334-14-287","volume":"14","author":"Piroth L.","year":"2014","unstructured":"Piroth L, Pechinot A, Di Martino V, Hansmann Y, Putot A, Patry I.  Evolving epidemiology and antimicrobial resistance in spontaneous bacterial peritonitis\u202f: A two-year observational study.","journal-title":"BMC Infect Dis"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.3748\/wjg.v18.i14.1700","volume":"18","author":"Kalambokis G.N.","year":"2012","unstructured":"Kalambokis GN, Mouzaki A, Rodi M, Tsianos EV.  Rifaximin for the prevention of spontaneous bacterial peritonitis.","journal-title":"World J Gastroenterol"},{"key":"ref=9","first-page":"p. 3\u201310","author":"Green S.","year":"2011","unstructured":"Green S, Higgins PTJ, Alderson P, Clarke M, Mulrow DC, Oxman DA.  Cochrane Handbook: Cochrane Reviews: Ch 8: Assessing risk of bias in included studies. In: Cochrane Handbook for: Systematic Reviews of Interventions."},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"Egger M.","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C.  Bias in meta-analysis detected by a simple, graphical test.","journal-title":"BMJ"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1002\/sim.1461","volume":"22","author":"Terrin N.","year":"2003","unstructured":"Terrin N, Schmid CH, Lau J, Olkin I.  Adjusting for publication bias in the presence of heterogeneity.","journal-title":"Stat Med"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5152\/tjg.2015.7782","volume":"26","author":"Mostafa T.","year":"2015","unstructured":"Mostafa T, Badra G, Abdallah M.  The efficacy and the immunomodulatory effect of rifaximin in prophylaxis of spontaneous bacterial peritonitis in cirrhotic Egyptian patients.","journal-title":"Turk J Gastroenterol"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s12072-015-9688-z","volume":"10","author":"Assem M.","year":"2016","unstructured":"Assem M, Elsabaawy M, Abdelrashed M, Elemam S, Khodeer S, Hamed W.  Efficacy and safety of alternating norfloxacin and rifaximin as primary prophylaxis for spontaneous bacterial peritonitis in cirrhotic ascites: A prospective randomized open-label comparative multicenter study.","journal-title":"Hepatol Int"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/jgh.12070","volume":"28","author":"Vlachogiannakos J.","year":"2013","unstructured":"Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, Karamanolis DG, Ladas SD.  Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis.","journal-title":"J Gastroenterol Hepatol"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ajme.2015.09.002","volume":"52","author":"Shamseya M.M.","year":"2016","unstructured":"Shamseya MM, Madkour MA.  Rifaximin: A reasonable alternative for norfloxacin in the prevention of spontaneous bacterial peritonitis in patients with HCV-related liver cirrhosis.","journal-title":"Alexandria J Med"},{"key":"ref=16","volume":"9","author":"Lutz P.","year":"2014","unstructured":"Lutz P, Parcina M, Bekeredjian-Ding I.  Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites.","journal-title":"PLoS One"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/MCG.0b013e3182506dbb","volume":"46","author":"Hanouneh M.A.","year":"2012","unstructured":"Hanouneh MA, Hanouneh IA, Hashash JG.  The Role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis.","journal-title":"J Clin Gastroenterol"}],"container-title":["Current Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/165608","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T15:27:41Z","timestamp":1557847661000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/165608\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,25]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,1,25]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389450119666180924145156","relation":{},"ISSN":["1389-4501"],"issn-type":[{"value":"1389-4501","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1,25]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-02-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}